Trails Edge Capital Partners LP Takes Position in ImageneBio, Inc. $IMA

Trails Edge Capital Partners LP acquired a new stake in shares of ImageneBio, Inc. (NASDAQ:IMA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 282,004 shares of the company’s stock, valued at approximately $1,663,824. Trails Edge Capital Partners LP owned about 2.48% of ImageneBio at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Blue Owl Capital Holdings LP acquired a new position in ImageneBio during the second quarter worth $5,414,000. Monashee Investment Management LLC bought a new stake in ImageneBio during the fourth quarter worth about $632,000. Cable Car Capital LP bought a new position in ImageneBio in the 2nd quarter worth $4,611,000. Goldman Sachs Group Inc. bought a new stake in shares of ImageneBio in the 4th quarter worth $76,000. Finally, Barclays PLC raised its stake in ImageneBio by 170.8% during the 4th quarter. Barclays PLC now owns 10,797 shares of the company’s stock worth $74,000 after acquiring an additional 6,810 shares during the period. 75.00% of the stock is owned by institutional investors.

ImageneBio Price Performance

IMA traded up $0.01 during trading on Friday, hitting $5.34. 4,583 shares of the stock traded hands, compared to its average volume of 146,566. The firm has a 50-day moving average of $5.77 and a 200 day moving average of $5.81. The firm has a market capitalization of $60.61 million, a P/E ratio of -1.17 and a beta of 0.76. ImageneBio, Inc. has a 12-month low of $3.94 and a 12-month high of $13.98.

ImageneBio (NASDAQ:IMA) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.27. As a group, equities analysts predict that ImageneBio, Inc. will post -3.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th. Wedbush reiterated an “underperform” rating on shares of ImageneBio in a report on Monday, May 11th. HC Wainwright assumed coverage on shares of ImageneBio in a research note on Friday, August 21st. They set a “buy” rating and a $28.00 price objective on the stock. Finally, Wall Street Zen cut shares of ImageneBio from a “sell” rating to a “strong sell” rating in a report on Sunday, May 17th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $29.00.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.